{ "FullStudy":{ "Rank":218267, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01510548", "OrgStudyIdInfo":{ "OrgStudyId":"HUM53" }, "Organization":{ "OrgFullName":"Kuopio University Hospital", "OrgClass":"OTHER" }, "BriefTitle":"ADALISKIAS: Adalimumab for Acute Disc Prolapse", "OfficialTitle":"Adalimumab (Anti TNF Alfa) in the Management of Acute Lumbar Disc Prolapses - a One Year, Randomized, Placebo Controlled, Double Blind, Single Center Trial" }, "StatusModule":{ "StatusVerifiedDate":"October 2013", "OverallStatus":"Unknown status", "LastKnownStatus":"Active, not recruiting", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"March 2007" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"July 2014", "PrimaryCompletionDateType":"Anticipated" }, "CompletionDateStruct":{ "CompletionDate":"July 2014", "CompletionDateType":"Anticipated" }, "StudyFirstSubmitDate":"January 2, 2012", "StudyFirstSubmitQCDate":"January 13, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 16, 2012", "StudyFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"October 10, 2013", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"October 11, 2013", "LastUpdatePostDateType":"Estimate" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Principal Investigator", "ResponsiblePartyInvestigatorFullName":"olavi airaksinen", "ResponsiblePartyInvestigatorTitle":"MD, PhD Ass Proff, Head of the Department of Rehabilitation", "ResponsiblePartyInvestigatorAffiliation":"Kuopio University Hospital" }, "LeadSponsor":{ "LeadSponsorName":"Kuopio University Hospital", "LeadSponsorClass":"OTHER" } }, "OversightModule":{ "OversightHasDMC":"No" }, "DescriptionModule":{ "BriefSummary":"Aims:\n\nTo study the efficacy and safety of adalimumab versus placebo in the treatment of acute disc prolapse will be will be compared up to 12 months after the start of study drug treatment.\n\nStudy type:\n\nA one year,randomized, placebo controlled double blind single center trial.\n\nPatients and study drug treatment:\n\nThe study population consist of 99 patients with sciatica caused by herniated disc prolapse.\n\nThe study has 3 arms: 33 patients randomized to adalimumab 40mg every week, 33 patients randomized to adalimumab 40mg every other week, and 33 patients randomized to placebo. Study drug treatment period will be six weeks.\n\nMethods:\n\nClinical evaluation, global assessments and Oswestry Disability Score and visual analog scale (VAS) will be used as the evaluation of clinical results with the disc prolapse patients confirmed by Magnetic Resonance Imaging. Health related quality of life will be assessed by 15-D questionnaire. Safety will be evaluated by medical examinations, adverse events (AE) collection and laboratory measurements throughout the study period.", "DetailedDescription":"Aims of this study:\n\nTNF alpha is believed to have a major role in the pathogenesis of sciatica. The efficacy and safety of adalimumab versus placebo in the treatment of acute disc prolapse will be will be compared up to 12 months after the start of study drug treatment. Primary objective of the study is to evaluate the clinical functionality of the patients with Oswestry Disability Score and VAS (leg and back pain) at the end of study drug treatment at week 6. Secondary objectives are to compare the need of operative treatment, sick leave days, pain killer consumption and quality of life between the two study groups up to 12 months after the start of study drug treatment.\n\nPatients and study drug treatment:\n\nThe study population consist of 99 patients with sciatica caused by herniated disc prolapse. The patients will be randomized to 3 arms: 33 patients to adalimumab 40mg every week, 33 patients to adalimumab 40mg every other week, and 33 patients to placebo. Study drug treatment period will be six weeks.\n\nThe study population will be collected from the patient population with severe sciatica symptoms sent to Spine Unit of Department of Physical and Rehabilitation Medicine in Kuopio University Hospital. The patient information will be given orally by investigators at the first visit and also patient information letter will be given. The informed consent will be signed by the patient and the investigator before any study related procedures. Patient will receive a copy of the written information and signed informed consent form. The patient has the right to discontinue his participation at any time without giving any reason.\n\nThe randomisation will be made in groups taken in count the level of disc prolapse and and sex. In emergency cases the randomisation will be opened with the decision of investigator. Each patient require 8 site visits. At the baseline visit (visit 0) the patient history and exclusion and inclusion criteria will be checked and MRI will be done. At visit 1 Visual Analogue Scale, Oswestry disability index and Quality of Life Questionnaire (15-D) and clinical examination of patients will be carried out. In case the MRI is already available at baseline visit, the visit can be combined with visit 1. At the follow up visits (1 week, 2 weeks, 4 weeks, 3 months, 6 months and 12 months after the first injection) Visual Analogue Scale, Oswestry disability index and Quality of Life Questionnaire (15-D), Patients and Physicians Global Assessments and clinical examination of patients will be carried out and the Adverse Events are recorded. If the the study medication do not help the sciatica symptoms enough, disc surgery will be evaluated with decision of investigator and neurosurgeon or orthopaedic surgeon at visit of 6 weeks. With very severe symptoms and signs, major neurological signs or intolerable pain the surgery will be evaluated in any phase of study (see rescue medication).\n\nThe patient data will be collected to CRF and source data to patient records, where also sick leave days and the use of pain medication will be collected during each site visit. Patient medication and history will be collected at visit 1. The Adverse Events will be evaluated at each visit and recorded to patient records and CRF.\n\nThis study is investigator based study and will be carried out on spine center at the Department of Physical and Rehabilitation Medicine in Kuopio University Hospital. The laboratory and imaging studies will be carried out in the Departments of Clinical Chemistry and Radiology. If the surgery is needed the Department of Neurosurgery and Orthopedics will be asked to work. The Abbott Laboratories Ltd will provide the study medication. Adalimumab is registered in Finland for Rheumatoid Arthritis. The study medication will be given at the site visit by investigator. Injections for week 3 and 5 will be administered by the study subject at home.\n\nEfficacy Assessments:\n\nTo confirm the clinical diagnosis of sciatica Magnetic Resonance Imaging using Siemens Avant 1.5 T clinical scanner (Siemens, Erlangen, Germany) will be used. Neural compromise will be assessed according to the system of Pfirrmann et al. from grade 0 (no compromise, normal) to Grade 1 (contact), Grade 2 (deviation) and Grade 3 (compression).\n\nSubjective disability will be measured by the Oswestry Disability Index (0-100%), where 0% represents no disability and 100 % extreme difficult disability.\n\nPain experience will be measured with self-administered visual analogue scale VAS (range 0-100 mm). It has proved to be a valid index of experimental, clinical and chronic pain.\n\nPatients and physicians Global Assessment will be used as the clinical evaluation of treatment.\n\nQuality of life will be assessed by Finnish 15-D questionnaire\n\nSafety Assessments:\n\nAt screening the patients must be evaluated for active and latent TB infections by using PPD and chest x-ray (if not available from previous 3 months prior to screening) and a detailed review of the subjects medical history. Also at screening T SPOT-TB test will be taken.\n\nAll patients who receive study drug will be included to the safety analysis. Safety follow-up will continue until 70 days after the last study drug injection. Safety will be assessed by AE collection, physical examination, vital signs and laboratory parameters throughout the study period. Safety laboratory parameters (full blood count, ALT, AST, CRP, ESR) will be evaluated at baseline and at the end of study drug treatment on week 6. Adverse Events will be reported to the local Ethics Committee and National Agency of Medicine according to the regulation 2/2004 Clinical Medicinal Trials on Humans.\n\nStatistical review:\n\nSample size:\n\nThe planned sample size of 33 in each arm is projected to provide 80% power to detect a mean difference of 25 in leg pain VAS at 6 weeks at a two-sided alpha level of 0.0125, assuming that the standard deviation is 20. For Oswestry Disability Index (ODI) 33 patients in each arm, would provide 80% power to detect a mean difference of 16 in ODI score at a two-sided alpha level of 0.0125, assuming a standard deviation of 13. Alpha-level of 0.0125 was selected to correct the multiple testing caused by two primary end-point variables and two comparisons for each variable, placebo versus the two different doses of active treatment. The sample size calculation is based on normality assumption; however the final analysis will be performed using non-parametric method. However the use of baseline value as covariate in the analysis should compensate the lost power due to the use of distribution free-method.\n\nStatistical analysis of the primary end-points:\n\nThe aim of the study is to demonstrate the efficacy of adalimumab versus placebo by means of Oswestry Disability Index and Leg Pain VAS at week 6. To maintain the overall 5% significance level of the primary end-points, Bonferroni adjustment will be applied, i.e. in the four significance tests applied to the primary hypothesis; p-value should be below 0.0125 to be considered as statistically significant.\n\nAs a primary analysis method, non-parametric analysis of covariance with baseline value as a covariate will be applied to ODI and Leg Pain VAS at week 6 separately for adalimumab 40 mg every week versus placebo and adalimumab 40 mg every other week versus placebo. Intent-to-treat population will be used in the primary analysis.\n\nAll patient data will be evaluated by intent-to-treat principle.\n\nFor the secondary end-points Bonferroni adjustment will be applied on end-point level.\n\nRescue medication:\n\nRescue medication will be arranged in case of lack of efficacy at the discretion of the investigator. If cauda equine symptoms or signs of large neurological defects will occur surgery will be performed. Also if the medication is considered a failure by the investigator's clinical judgment the patients will have the opportunity to be evaluated for disc surgery." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Disc Prolapse", "Pain" ] }, "KeywordList":{ "Keyword":[ "Disc prolapse", "Pain", "Disability" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 3" ] }, "DesignInfo":{ "DesignAllocation":"Randomized", "DesignInterventionModel":"Parallel Assignment", "DesignPrimaryPurpose":"Treatment", "DesignMaskingInfo":{ "DesignMasking":"Triple", "DesignWhoMaskedList":{ "DesignWhoMasked":[ "Participant", "Investigator", "Outcomes Assessor" ] } } }, "EnrollmentInfo":{ "EnrollmentCount":"90", "EnrollmentType":"Anticipated" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"Adalimumab 20 mg per week", "ArmGroupType":"Active Comparator", "ArmGroupDescription":"Patient will get at double blind situation adalimumab 20 mg every week (six injections) injections", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Biological: Adalimumab injections for acute disc prolapse patients" ] } },{ "ArmGroupLabel":"Adalimumab 40 mg per week", "ArmGroupType":"Active Comparator", "ArmGroupDescription":"Patient will get at double blind situation adalimumab 40 mg per week injections", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Biological: Adalimumab injections for acute disc prolapse patients" ] } },{ "ArmGroupLabel":"placebo arm", "ArmGroupType":"Placebo Comparator", "ArmGroupDescription":"Patient will get at double blind situation placebo (= NaCl liquid solution, absolutely same color as the active drug) injections one per week during six weeks - same as the adalimumab arms", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Biological: Adalimumab injections for acute disc prolapse patients" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Biological", "InterventionName":"Adalimumab injections for acute disc prolapse patients", "InterventionDescription":"see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Adalimumab 20 mg per week", "Adalimumab 40 mg per week", "placebo arm" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "Biologic Drugs for ischias", "Humira for ischias" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"Pain", "PrimaryOutcomeDescription":"As primary endpoint the functionality of the patients measured by Oswestry Disability Score and VAS (leg and back pain) will be evaluated and the proportion of patients in each group for the need of surgery at week 6 at the end of the study drug injections.", "PrimaryOutcomeTimeFrame":"one year" } ] }, "SecondaryOutcomeList":{ "SecondaryOutcome":[ { "SecondaryOutcomeMeasure":"need for operative treatment and functional status = proportion of patients operated after one year", "SecondaryOutcomeDescription":"As secondary endpoints functionality of the patient, need of operative treatment, sick leave days and pain killer consumption will be evaluated at week 1, 2, 4 and 6, 3 months, 6 months and 12 months 1 year after the start of study treatment.", "SecondaryOutcomeTimeFrame":"one year" },{ "SecondaryOutcomeMeasure":"safety in general", "SecondaryOutcomeDescription":"All patients who receive study medication will be included to the safety analysis.\n\nBlood tests before and after administration will be analysed. Vital signs and clinical examination will be recorded on each visits All adverse and serious adverse events will be evaluated in connection to study medication during the follow-up time.", "SecondaryOutcomeTimeFrame":"During one year follow up." } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nMales and females over 18 years of age\nAble and willing to give written informed consent\nAcute or subacute (no more than 2 months) clinical sciatica symptoms caused by herniated disc prolapse confirmed by Magnetic Resonance Imaging (MRI).\nOswestry Disability Score at least 16% at entry.\nVAS (leg and back pain) at least 40 mm at entry.\nAble and willing to self-administer s.c. injections or have available a suitable person to administer s.c. injections.\nA negative pregnancy test (serum HCG) for women of childbearing potential prior to start of study treatment.\n\nExclusion criteria:\n\nPrior treatment with any investigational agent within 30 days, or five half lives of the product whichever is longer.\nPrior treatment with infliximab or etanercept.\nHistory of chronic back pain.\nPreviously operated disc prolapse or other spinal column operation\nUncontrolled diabetes, unstable ischemic heart disease, congestive heart failure (NYHA III-IV), recent stroke (within three months), chronic leg ulcer and any other condition (e.g. indwelling urinary catheter) which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.\nHistory of cancer or malignant lymphoproliferative disease other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.\nPositive serology for hepatitis B or C indicating active infection.\nHistory of positive HIV status.\nPersistent or recurrent infections or severe infections requiring hospitalization or treatment with i.v. antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment.\nPrevious diagnosis or signs highly indicative of central nervous system demyelinating diseases (e.g. optic neuritis, ataxia, apraxia).\nHistory of active tuberculosis, histoplasmosis or listeriosis.\nFemale subjects who are pregnant or breast-feeding.", "HealthyVolunteers":"No", "Gender":"All", "MinimumAge":"18 Years", "MaximumAge":"75 Years", "StdAgeList":{ "StdAge":[ "Adult", "Older Adult" ] } }, "ContactsLocationsModule":{ "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Olavi Airaksinen, MD", "OverallOfficialAffiliation":"MD, Head of Department of PRM", "OverallOfficialRole":"Principal Investigator" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"Kuopio University Hospital", "LocationCity":"Kuopio", "LocationZip":"70210", "LocationCountry":"Finland" } ] } }, "ReferencesModule":{ "ReferenceList":{ "Reference":[ { "ReferencePMID":"13130150", "ReferenceType":"background", "ReferenceCitation":"Cooper RG, Freemont AJ. TNF-alpha blockade for herniated intervertebral disc-induced sciatica: a way forward at last? Rheumatology (Oxford). 2004 Feb;43(2):119-21. Epub 2003 Sep 16." },{ "ReferencePMID":"15288398", "ReferenceType":"background", "ReferenceCitation":"Cuellar JM, Montesano PX, Carstens E. Role of TNF-alpha in sensitization of nociceptive dorsal horn neurons induced by application of nucleus pulposus to L5 dorsal root ganglion in rats. Pain. 2004 Aug;110(3):578-87." },{ "ReferencePMID":"15115710", "ReferenceType":"background", "ReferenceCitation":"Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis. 2004 Sep;63(9):1120-3. Epub 2004 Apr 28." } ] } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"D000068879", "InterventionMeshTerm":"Adalimumab" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000000893", "InterventionAncestorTerm":"Anti-Inflammatory Agents" },{ "InterventionAncestorId":"D000018501", "InterventionAncestorTerm":"Antirheumatic Agents" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M326", "InterventionBrowseLeafName":"Adalimumab", "InterventionBrowseLeafAsFound":"Adalimumab", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M2798", "InterventionBrowseLeafName":"Anti-Inflammatory Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M19188", "InterventionBrowseLeafName":"Antirheumatic Agents", "InterventionBrowseLeafRelevance":"low" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"Infl", "InterventionBrowseBranchName":"Anti-Inflammatory Agents" },{ "InterventionBrowseBranchAbbrev":"ARhu", "InterventionBrowseBranchName":"Antirheumatic Agents" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000007405", "ConditionMeshTerm":"Intervertebral Disc Displacement" },{ "ConditionMeshId":"D000011391", "ConditionMeshTerm":"Prolapse" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000020763", "ConditionAncestorTerm":"Pathological Conditions, Anatomical" },{ "ConditionAncestorId":"D000013122", "ConditionAncestorTerm":"Spinal Diseases" },{ "ConditionAncestorId":"D000001847", "ConditionAncestorTerm":"Bone Diseases" },{ "ConditionAncestorId":"D000009140", "ConditionAncestorTerm":"Musculoskeletal Diseases" },{ "ConditionAncestorId":"D000006547", "ConditionAncestorTerm":"Hernia" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M11649", "ConditionBrowseLeafName":"Pain", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M12844", "ConditionBrowseLeafName":"Prolapse", "ConditionBrowseLeafAsFound":"Prolapse", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M9022", "ConditionBrowseLeafName":"Intervertebral Disc Displacement", "ConditionBrowseLeafAsFound":"Disc Prolapse", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M21103", "ConditionBrowseLeafName":"Pathological Conditions, Anatomical", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M14502", "ConditionBrowseLeafName":"Spinal Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M3708", "ConditionBrowseLeafName":"Bone Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M10680", "ConditionBrowseLeafName":"Musculoskeletal Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M8208", "ConditionBrowseLeafName":"Hernia", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC23", "ConditionBrowseBranchName":"Symptoms and General Pathology" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" },{ "ConditionBrowseBranchAbbrev":"BC05", "ConditionBrowseBranchName":"Muscle, Bone, and Cartilage Diseases" } ] } } } } } }